To determine if this signalling pathway also mediates the synergistic anti-MM effects of EGCG plus eriodictyol in vivo, mice with palpable tumours following MPC-11 cell inoculation were injected with 15 mg/kg EGCG (i.p.), 15 mg/kg eriodictyol (i.p.), or both, and signalling activity examined in tumour tissue lysates by colorimetric enzyme assays (Akt, ASA) and tissue sections by fluorescence immunohistochemistry (protein kinase C delta (PKCδ)and eNOS. This evidence concerns the gene AKT1 and neoplasm.